相关实验视频
Updated: Jun 10, 2025
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.6K
如何使心脏病学临床试验更加包容?
Faiez Zannad1,2, Otavio Berwanger3,4, Stefano Corda5
1Université de Lorraine, Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. f.zannad@chru-nancy.fr.
Nature medicine
|October 14, 2024
概括
临床试验必须提高多样性. 策略包括更广泛的招聘,文化敏感的沟通和多样化的试验团队,以确保心血管研究反映患者群体.
科学领域:
- 心血管研究的心血管研究.
- 临床试验方法论 临床试验方法论
- 卫生公平性健康公平性
背景情况:
- 与人口疾病患病率相比,心血管临床试验经常低于代表儿童,老年人,女性和少数民族等关键人口统计数据.
- 这种差异限制了试验结果在不同患者群体的概括性和适用性.
研究的目的:
- 概述可行的策略,以提高心血管临床试验的代表性.
- 在试验融资,设计,实施和传播阶段提出改进建议.
主要方法:
- 审查和综合当前的最佳实践和建议的干预措施,以增加试验多样性.
- 专注于招聘策略,地点选择,排除标准,实用性试验设计 (嵌入式,分散式),文化上适当的沟通,以及与患者代表的共同设计.
- 强调多样化试验领导和利用资助机构和期刊的报告要求.
主要成果:
- 通过包容性招聘和选址,尽量减少患者负担的务实设计和文化定制的沟通,可以实现更好的代表性.
- 让多样化的患者群体参与试验共同设计和多样化试验领导是培养信任和改善参与的关键.
- 资助者和期刊对社会人口统计数据报告的需求增加,以及监管指导,可以推动进步.
结论:
- 实施多方面的方法来解决资金,设计,进行和传播对于改善心血管试验多样性至关重要.
- 多样化试验参与和领导力对于推进心血管医学中的健康公平至关重要.
- 拟议的战略提供了一个可转移的框架,以提高超越心血管试验的临床研究中的代表性.
相关概念视频
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:16Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
105
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
105
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
2
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
2
01:30Coronary Artery Disease III: Clinical Manifestations
3
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
3